[Translation] An open-label, non-randomized, single-arm, single-dose, dose-escalating Phase I/IIa clinical study to evaluate the safety, tolerability and pharmacokinetics of AL-001 ophthalmic injection in patients with wet age-related macular degeneration (wAMD)
评价SCS 注射AL-001 眼用注射液在wAMD 患者中的安全性、耐受性、PK 特征、免疫原性和初步有效性以及病毒的脱落,探索细胞免疫性,为后续的临床试验推荐科学合理的临床剂量。
[Translation] To evaluate the safety, tolerability, PK characteristics, immunogenicity, preliminary efficacy and viral shedding of SCS-injected AL-001 ophthalmic injection in wAMD patients, explore cellular immunity, and recommend scientifically reasonable clinical doses for subsequent clinical trials.